Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Restructuring Costs (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Restructuring Costs for 11 consecutive years, with $48000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Restructuring Costs fell 73.18% to $48000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $350000.0, a 39.13% decrease, with the full-year FY2022 number at -$233000.0, down 177.67% from a year prior.
  • Restructuring Costs was $48000.0 for Q3 2025 at Harvard Bioscience, up from $30000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $5.2 million in Q1 2022 to a low of -$4.9 million in Q2 2022.
  • A 4-year average of $88111.1 and a median of $93000.0 in 2025 define the central range for Restructuring Costs.
  • Biggest YoY gain for Restructuring Costs was 73.18% in 2025; the steepest drop was 92.42% in 2025.
  • Harvard Bioscience's Restructuring Costs stood at $300000.0 in 2021, then plummeted by 281.33% to -$544000.0 in 2022, then surged by 132.9% to $179000.0 in 2024, then crashed by 73.18% to $48000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Restructuring Costs are $48000.0 (Q3 2025), $30000.0 (Q2 2025), and $93000.0 (Q1 2025).